Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT

International Journal of Molecular Medicine

Volumn 24, Issue 6, 2009, Pages 733-741

  Osawa, Naoshi ^a   Onoda, Naoyoshi ^a   Kawajiri, Hidemi ^a   Tezuka, Kenji ^a   Takashima, Tsutomu ^a   Ishikawa, Tetsuro ^a   Miyauchi, Akira ^b   Hirokawa, Mitsuyoshi ^b   Wakasa, Kenichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMA HOSPITAL   (Japan)

Author keywords

hTERT; MIB 1; Nucleolin; Parathyroid carcinoma

Indexed keywords

KI 67 ANTIGEN; NUCLEOLIN; PROTEIN ANTIBODY; TELOMERASE REVERSE TRANSCRIPTASE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; TELOMERASE;

EID: 70350768845     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000286     Document Type: Article

References (45)

1. Ihara M, Okamoto T, Suzuki R, Kawamata A, Nishikawa T, Kobayashi M and Obara T: Functional parathyroid carcinoma: Long-term treatment outcome and risk factor analysis. Surgery 142: 936-943, 2007.
2. Wang CA and Gaz RD: Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149: 522-527, 1985.
3. Shane E: Clinical Review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493, 2001.
4. Rodgers SE and Perrier ND: Parathyroid carcinoma. Curr Opin Oncol 18: 16-22, 2006.
5. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY and Clark OH: Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115: 334-344, 2009.
6. Lee PK, Jarosek SL, Virnig BA, Evasovich M and Tuttle TM: Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109: 1736-1741, 2007.
7. Arslan N and Rydzewski B: Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 27: 221-222, 2002.
8. Neumann DR, Esselstyn CB and Kim EY: Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi- SPECT findings. J Nucl Med 37: 2000-2001, 1996.
9. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds): WHO Classification of Tumor Pathology and Genetics of Tumors of Endocrine Organs. IARC Press, Lyon, 2004.
10. Naccarato AG, Marcocci C, Miccoli P, Bonadio AG, Cianferotti L, Vignali E, Cipollini G and Viacava P: Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Invest 21: 136-141, 1998.
11. Vargas MP, Vargas HI, Kleiner DE and Merino MJ: The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10: 12-17, 1997.
12. Hadar T, Shvero J, Yaniv E, Ram E, Shvili I and Koren R: Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 11: 45-49, 2005.
13. Karak AK, Sarkar C, Chumber S and Tandon N: MIB-1 proliferative index in parathyroid adenoma & hyperplasia. Indian J Med Res 105: 235-238, 1997.
14. Farnebo F, Auer G, Farnebo L, Teh B, Twigg S, Aspenblad U, Thompson N, Grimelius L, Larsson C and Sandelin K: Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23: 68-74, 1999.
15. Kameyama K, Takami H, Umemura S, Osaruma Y, Wada N, Sugino K, Mimura T and Ito K: PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 7: 301-305, 2000.
16. Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, Brennan MF, Singh B and Ghossein R: Parathyroid neoplasms: Clinical, histopathological, and tissue microarraybased molecular analysis. Hum Pathol 34: 54-64, 2003.
17. Lumachi F, Ermani M, Marino F, Iacobone M, Baldessin M, Cappuzzo G, Zanella S and Favia G: PCNA-LI, Ki-67 immunostaining, p53 activity and histopathological variables in parathyroid carcinoma. Anticancer Res 26: 1305-1308, 2006.
18. Bergero N, Pompa RD, Sacerdote C, Gasparri G, Volante M, Bussolati G and Papotti M: Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36: 908-914, 2005.
19. Onoda N, Ogisawa K, Ishikawa T, Takenaka C, Tahara H, Inaba M, Takashima T and Hirakawa K: Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today 34: 389-393, 2004.
20. Falchetti A, Becherini L, Martineti V, Morelli A, Benvenuti S, Picariello L, Gennari L, Lampugnani R, Bordi C and Brandi ML: Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma. Biochem Biophys Res Commun 265: 252-255, 1999.
21. Kammori M, Nakamura K, Ogawa T, Mafune K, Tatsunori Y, Obara T, Onoda N, Fujiwara M, Izumiyama-Shimomura N, Mori M, Kaminishi M and Takubo K: Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol 58: 43-48, 2003.
22. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T and Inoue M: Significance of immunological detection of human telomerase reverse transcriptase: Re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 163: 859-867, 2003.
23. Kammori M, Nakamura K, Kanauchi H, Obara T, Kawahara M, Mimura Y, Kaminishi M and Takubo K: Consistent decrease in telomerase length in parathyroid tumors but alteration in telomerase activity limited to malignancies: Preliminary report. World J Surg 26: 1083-1087, 2002.
24. Iwata T, Inoue K, Morita R, Mizuguchi S, Tsukioka T, Onoda N and Suehiro S: Functional large parathyroid carcinoma extending into the superior mediastinum. Ann Thorac Cardiovasc Surg 14: 112-115, 2008.
25. Tezuka K, Onoda N, Takashima T, Ishikawa T, Wakasa T, Wakasa K and Hirakawa K: Clinical significance of intratumoral sinusoidal structures showing lympho-endothelial immunoreactivity in breast cancer. Oncol Rep 20: 25-32, 2008.
26. Cryns VL, Rubio MP, Thor AD, Louis DN and Arnold A: p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78: 1320-1324: 1994.
27. Szende B, Farid P, Vegso G, Perner F and Kopper L: Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism. Pathol Oncol Res 10: 98-103, 2004.
28. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA and Lloyd RV: Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27 protein. Am J Surg Pathol 23: 288-295, 1999.
29. Saggiorato E, Bergero N, Volante M, Bacillo E, Rosas R, Gasparri G, Orlandi F and Papotti M: Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol 126: 59-66, 2006.
30. Thomopoulou GE, Tseleni-Balafouta S, Lazaris AC, Koutselini H, Kavantzas N and Davaris PS: Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells on parathyroid lesions. Eur J Endocrinol 148: 81-87, 2003.
31. Zachos I, Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Papatsoris AG, Podimatas T, Papachristodoulou A, Chrisofos M, Deliveliotis C and Papavassiliou AG: Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol 135: 1169-1175, 2009.
32. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Ardai J, Lanotte M, Tong JH, Chen GQ and Segal-Bendirdjian E: Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 119: 2797-2806, 2006.
33. Ginisty H, Sicard H, Roger B and Bouvet P: Structure and function of nucleolin. J Cell Sci 112: 761-772, 1999.
34. Srivastava M and Pollard HB: Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 13: 1911-1922, 1999.
35. Ishikawa F, Matunis MJ, Dreyfuss G and Cech TR: Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. Mol Cell Biol 13: 4301-4310, 1993.
36. Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, Hayashi N, Hahn WC and Murakami S: Nucleolin interacts with telomerase. J Biol Chem 279: 51508-51515, 2004.
37. Wong JY, Kusdra L and Collins K: Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 4: 731-736, 2002.
38. Kotoula V, Cheva A, Barbanis S, Papadimitriou CS and Karkavelas G: hTERT immunopositivity patterns in the normal brain and in astrocytic tumors. Acta Neuropathol 111: 569-578, 2006.
39. Yan P, Benhattar J, Seelentag W, Stehle JC and Bosman FT: Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 121: 391-397, 2004.
40. Casalbore P, Budoni M, Ricci-Vitiani L, Cenciarelli C, Petrucci G, Milazzo L, Mintano N, Tabolacci E, Maira G, Larocca LM and Pallini R: Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS ONE 4: e4434, 2009.
41. Madej P, Plewka A, Madej JA, Dzimira S, Nowak M, Plewka D and Nowaczyk G: Immunohistochemical localization of telomerase in myomas and in uterine myometrium. Pathol Res Pract 204: 637-642, 2008.
42. Zendehrokh N, Rehnberg J and Dejmek A: Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions. Acta Cytol 51: 886-892, 2007.
43. Kyo S, Takakura M, Fujiwara T and Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99: 1528-1538, 2008.
44. Välimäki S, Forsberg L, Farnebo LO and Larsson C: Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 21: 727-735, 2002.
45. Hewitt KM, Sharma PK, Samowitz W and Hobbs M: Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 116: 928-933, 2007.